Annual Cash & Cash Equivalents
$77.39 M
-$92.81 M-54.53%
December 31, 2024
Summary
- As of March 12, 2025, AMLX annual cash & cash equivalents is $77.39 million, with the most recent change of -$92.81 million (-54.53%) on December 31, 2024.
- During the last 3 years, AMLX annual cash & cash equivalents has risen by +$27.20 million (+54.19%).
- AMLX annual cash & cash equivalents is now -54.53% below its all-time high of $170.20 million, reached on December 31, 2023.
Performance
AMLX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$77.39 M
+$5.55 M+7.73%
December 31, 2024
Summary
- As of March 12, 2025, AMLX quarterly cash and cash equivalents is $77.39 million, with the most recent change of +$5.55 million (+7.73%) on December 31, 2024.
- Over the past year, AMLX quarterly cash and cash equivalents has dropped by -$92.81 million (-54.53%).
- AMLX quarterly cash and cash equivalents is now -68.76% below its all-time high of $247.76 million, reached on June 30, 2023.
Performance
AMLX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AMLX Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -54.5% | -54.5% |
3 y3 years | +54.2% | -42.8% |
5 y5 years | +2425.0% | -42.8% |
AMLX Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -54.5% | +54.2% | -68.8% | +54.2% |
5 y | 5-year | -54.5% | +2425.0% | -68.8% | +501.0% |
alltime | all time | -54.5% | +2425.0% | -68.8% | +501.0% |
Amylyx Pharmaceuticals Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $77.39 M(-54.5%) | $77.39 M(+7.7%) |
Sep 2024 | - | $71.84 M(-4.2%) |
Jun 2024 | - | $75.00 M(-56.0%) |
Mar 2024 | - | $170.55 M(+0.2%) |
Dec 2023 | $170.20 M(+172.2%) | $170.20 M(+25.8%) |
Sep 2023 | - | $135.26 M(-45.4%) |
Jun 2023 | - | $247.76 M(+116.3%) |
Mar 2023 | - | $114.56 M(+83.2%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2022 | $62.53 M(+24.6%) | $62.53 M(-42.0%) |
Sep 2022 | - | $107.73 M(+59.7%) |
Jun 2022 | - | $67.44 M(-38.9%) |
Mar 2022 | - | $110.40 M(+120.0%) |
Dec 2021 | $50.19 M(+289.8%) | $50.19 M(-34.5%) |
Sep 2021 | - | $76.68 M(+495.5%) |
Dec 2020 | $12.88 M(+320.1%) | $12.88 M |
Dec 2019 | $3.06 M | - |
FAQ
- What is Amylyx Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Amylyx Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Amylyx Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of AMLX is $77.39 M
What is the all time high annual cash & cash equivalents for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high annual cash & cash equivalents is $170.20 M
What is Amylyx Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, AMLX annual cash & cash equivalents has changed by -$92.81 M (-54.53%)
What is Amylyx Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AMLX is $77.39 M
What is the all time high quarterly cash and cash equivalents for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high quarterly cash and cash equivalents is $247.76 M
What is Amylyx Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, AMLX quarterly cash and cash equivalents has changed by -$92.81 M (-54.53%)